The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Treatment for the hepatitis C virus (HCV) has progressed significantly over recent years with the arrival of new antiviral molecules targeting the virus specifically and directly. Traditional dual therapies combining interferon and ribavirin firstly evolved towards triple therapies combining a protease inhibitor, then towards new combinations of two, three or even four drugs, generally eliminating...
Due to the relatively high cost of the antiviral therapies used to treat the hepatitis C virus (HCV), access to these medications is prioritised. The indications, currently restricted to patients with at least hepatic fibrosis at a moderate to severe stage, are set to gradually widen. The treatment strategy is based on one or several second generation direct-acting antivirals, combining or not ribavirin...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.